Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Sensors (Basel) ; 24(12)2024 Jun 13.
Artigo em Inglês | MEDLINE | ID: mdl-38931622

RESUMO

Thanks to advancements in silicon photomultiplier sensors (SiPMs) and system-on-chip (SoC) technology, our INFN Roma1 group developed ArduSiPM in 2012, the first all-in-one scintillator particle detector in the literature. It used a custom Arduino Due shield to process fast signals, utilizing the Microchip Sam3X8E SoC's internal peripherals to control and acquire SiPM signals. The availability of radiation-tolerant SoCs, combined with the goal of reducing system space and weight, led to the development of an innovative second-generation board, a better-performing device called Cosmo ArduSiPM, suitable for space missions. The architecture of the new detector is based on the Microchip SAMV71 300 MHz, 32-bit ARM® Cortex®-M7 (Microchip Technology Inc., Chandler, AZ, USA). While the analog front-end is essentially identical to the ArduSiPM, it utilizes components with the smallest possible package. The board fits in a CubeSat module. Thanks to the compact design, the board has two independent channels, with a total weight of only 40 grams within a CubeSat form factor. The ArduSiPM architecture is based on a single microcontroller and fast discrete analog electronics. It benefits from the continued development of SoCs related to the IoT (Internet of Things) market. Compared with a system with a custom ASIC, this architecture based on software and SoC capabilities offers considerable advantages in terms of cost and development time. The ability to incorporate new commercial SoCs, continuously emerging from advancements in the aerospace and automotive industries, provides the system with a robust foundation for sustained growth over the years. A detailed characterization of the hardware and the system's response to different photon fluxes is presented in this article. Additionally, coupling the device with a scintillator was tested at the end of this article as a preliminary trial for future measurements, showing potential for further enhancement of the detector's capabilities.

2.
J Nucl Med ; 56(1): 3-8, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25500828

RESUMO

UNLABELLED: A novel radioguided surgery (RGS) technique for cerebral tumors using ß(-) radiation is being developed. Checking for a radiotracer that can deliver a ß(-) emitter to the tumor is a fundamental step in the deployment of such a technique. This paper reports a study of the uptake of (90)Y-DOTATOC in meningiomas and high-grade gliomas (HGGs) and a feasibility study of the RGS technique in these types of tumor. Estimates were performed assuming the use of a ß(-) probe under development with a sensitive area 2.55 mm in radius to detect 0.1-mL residuals. METHODS: Uptake and background from healthy tissues were estimated on (68)Ga-DOTATOC PET scans of 11 meningioma patients and 12 HGG patients. A dedicated statistical analysis of the DICOM images was developed and validated. The feasibility study was performed using full simulation of emission and detection of the radiation, accounting for the measured uptake and background rate. RESULTS: All meningioma patients but one with an atypical extracranial tumor showed high uptake of DOTATOC. In terms of feasibility of the RGS technique, we estimated that by administering a 3 MBq/kg activity of radiotracer, the time needed to detect a 0.1-mL remnant with 5% false-negative and 1% false-positive rates is less than 1 s. Actually, to achieve a detection time of 1 s the required activities to administer were as low as 0.2-0.5 MBq/kg in many patients. In HGGs, the uptake was lower than in meningiomas, but the tumor-to-nontumor ratio was higher than 4, which implies that the tracer can still be effective for RGS. It was estimated that by administering 3 mBq/kg of radiotracer, the time needed to detect a 0.1-mL remnant is less than 6 s, with the exception of the only oligodendroma in the sample. CONCLUSION: Uptake of (90)Y-DOTATOC in meningiomas was high in all studied patients. Uptake in HGGs was significantly worse than in meningiomas but was still acceptable for RGS, particularly if further research and development are done to improve the performance of the ß(-) probe.


Assuntos
Partículas beta , Glioma/cirurgia , Neoplasias Meníngeas/cirurgia , Meningioma/cirurgia , Octreotida/análogos & derivados , Somatostatina/análogos & derivados , Cirurgia Assistida por Computador/métodos , Transporte Biológico , Glioma/metabolismo , Glioma/patologia , Humanos , Neoplasias Meníngeas/metabolismo , Meningioma/metabolismo , Gradação de Tumores , Octreotida/química , Octreotida/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA